Neurocrine Biosciences

Yahoo Finance • 4 days ago

Catalyst Watch: Earnings heat up, Fedspeak flurry, and eyes on space

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • 7 days ago

Neurocrine to acquire Soleno in $2.9bn transaction

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value. The transaction will expand Neurocrine’s portfolio in endocri... Full story

Yahoo Finance • 7 days ago

Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 Stocks With Unexpected Gains. Soleno Therapeutics soared by 32.31 percent on Monday to close at $52.25 apiece, as investors gobbled up shares following news that it is set to be acqu... Full story

Yahoo Finance • 8 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)

BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story

Yahoo Finance • 8 days ago

Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share

Soleno Therapeutics logo Key Points Neurocrine will acquire Soleno in an all-cash tender offer at $53 per share, valuing the deal at about $2.9 billion, funded with cash on hand and not subject to a financing condition. VYKAT XR, approve... Full story

Yahoo Finance • 8 days ago

Top Midday Stories: Iran Reportedly Rejects Proposed Ceasefire; Soleno Shares Rise After $2.9 Billion Neurocrine Deal

All three major US stock indexes were edging higher in late-morning trading Monday as investors weig PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • 8 days ago

Ceasefire Prospects in Focus as US Equity Futures Trade Mixed Pre-Bell

US equity futures were mixed ahead of Monday's opening bell as traders weighed prospects for a Middl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

SLNO Jumps As Deal Buzz Lifts Stocks

This article first appeared on GuruFocus. Soleno Therapeutics (NASDAQ:SLNO) is stealing the spotlight early Monday, jumping 26% premarket as deal talks drive the biggest moves. The surge follows reports that Neurocrine Biosciences (NASDA... Full story

Yahoo Finance • 8 days ago

Nasdaq futures climb as investors weigh oil swings, jobs report exceeds expectations

Nasdaq futures climb as investors weigh oil swings, jobs report exceeds expectations Proactive uses images sourced from Shutterstock 8:10am: Oil pulls back from highs Stocks look set for a cautious but slightly upbeat open, with futures... Full story

Yahoo Finance • 8 days ago

Stocks Mostly Rise Pre-Bell as Traders Monitor Middle East War Developments

The benchmark US stock measures were mostly tracking in the green before Monday's opening bell as tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.

Soleno Therapeutics stock surged 40% in premarket trading Monday after Neurocrine Biosciences announced it had agreed to buy the company in a deal worth $2.9 billion. Neurocrine Biosciences said that it had agreed to buy Soleno—the maker o... Full story

Yahoo Finance • 8 days ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

April 6 (Reuters) - Neurocrine Biosciences will acquire rare disease drugmaker ‌Soleno Therapeutics for $2.9 billion in ‌cash, the companies said on Monday, marking ​the neuroscience-focused drugmaker's expansion into metabolic disorders.... Full story

Yahoo Finance • 8 days ago

Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks

[Acquisition] anilakkus/iStock via Getty Images * Soleno Therapeutics (SLNO [https://seekingalpha.com/symbol/SLNO]) shares rose over 30% premarket on Monday following a _Financial Times_ report that Neurocrine Biosciences (NBIX [https:/... Full story

Yahoo Finance • 22 days ago

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new position in Biohaven Ltd.(NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing. What happened Accor... Full story

Yahoo Finance • 28 days ago

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Rat... Full story

Yahoo Finance • 2 months ago

Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum

Earnings Call Insights: Neurocrine Biosciences (NBIX) Q4 2025 MANAGEMENT VIEW * CEO Kyle Gano highlighted that "As Neurocrine enters 2026, our foundation is stronger than at any point in our more than 30-year history and it continues t... Full story

Yahoo Finance • 4 months ago

Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal

(RTTNews) - Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy (DCP) did not meet its primary or key secondary endpoints.... Full story

Yahoo Finance • 5 months ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 5 months ago

Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.

Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments... Full story